Experienced in Wilms Tumor

Jun F. Jiang

No. 25 Taiping Street, 
Luzhou, CN 
Experienced in Wilms Tumor
No. 25 Taiping Street, 
Luzhou, CN 
OverviewLocationsClinical Research

Overview

Jun Jiang practices in Luzhou, China. Mr. Jiang is rated as an Experienced expert by MediFind in the treatment of Wilms Tumor. His top areas of expertise are Breast Cancer, Von Hippel-Lindau (VHL) Syndrome, Prostate Cancer, Mastectomy, and Thyroidectomy.

His clinical research consists of co-authoring 224 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Wilms Tumor.

Gender
Male

Locations

No. 25 Taiping Street, Luzhou, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer
Enrollment Status: Unknown
Publish Date: April 19, 2017
Intervention Type: Drug
Study Drugs: 5-Fu/Epirubicin/CTX Following Docetaxel, Docetaxel/Capecitabine Followed by Capecitabine/Epirubicin/Cyclophosphamide
Study Phase: Phase 3
View 1 Less Clinical Trial

224 Total Publications

Association between C-reactive protein-albumin-lymphocyte (CALLY) index with intravenous immunoglobulin non-response in Kawasaki disease.
Association between C-reactive protein-albumin-lymphocyte (CALLY) index with intravenous immunoglobulin non-response in Kawasaki disease.
Journal: Annals of medicine
Published: August 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jiang's expertise for a condition
ConditionClose
    View All 36 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile